Paris, March 23, 2010 – Cellectis (Alternext: ALCLS), the French genome engineering specialist, announces today that Frédéric Pâques, PhD, Chief Scientific Officer, will present Cellectis’ technologies and their application in genome surgery at the 7th British Society for Gene Therapy Annual Conference to be held at Royal Holloway, University of London, on March 29-31, 2010.
Targeted approaches have emerged today as an alternative to current random insertion strategies for gene therapy. Such approaches include the targeted insertion of therapeutic transgenes into chosen loci, the precise editing of deleterious mutation (gene correction), as well as various gene deletion and knock-out strategies. A variety of different tools have been envisioned, including integrases, recombinases, transposases and endonucleases. Meganucleases, the most specific endonucleases, represent ideal tools for precise genome editing or genome surgery.
Dr Pâques will discuss the use of “Meganucleases for genome surgery” on March 30, 2010, at 9.20AM, during an oral session on Genome Engineering.
More information : http://www.cellectis.com/
